Facebook
Twitter
LinkedIn
Forward
Core Antimicrobial Stewardship Curriculum Self - Study
The IDSA Core Antimicrobial Stewardship (CAS) Curriculum was developed to provide infectious diseases (ID) fellows with foundational education and training in Antimicrobial
Stewardship (AS), regardless of ultimate career plans. The self-study version of the curriculum is available to learners who are not currently in a fellowship program and seeking independent study of antimicrobial stewardship.
Access to the curriculum will be provided for two years, and the estimated time of completion is 15 hours.
The Core Antimicrobial Stewardship (CAS) Curriculum was featured in the November 2023 episode of Febrile. Check out the podcast below:
Target Audience
Infectious Disease professionals who desire to learn more about antimicrobial stewardship but are not in a participating fellowship program, no longer in fellowship, or generally would like to gain more knowledge on the subject.
Learning Objectives
Upon completion of this Curriculum, you should be able to:
1. Explain to patients and health care providers the importance of antibiotic stewardship in the care of individual patients and the community at large
2. Model antibiotic stewardship best practices during the clinical care of patients in the inpatient and outpatient setting
3. Structure a conversation to effect change in the antibiotic prescribing patterns of other providers using techniques based in behavioral psychology
4. Describe elements of an effective antibiotic stewardship program and explain the inter-professional collaborations and leadership support necessary for its success
Additional Information
| Attachment | Size |
|---|---|
 CAS Curriculum Purchasing Information | 172.72 KB |
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found.
All relevant financial relationships have been mitigated.
| Name | Individual's role in activity | Name of commercial interest | Nature of Relationship |
|---|---|---|---|
| Advani, Sonali | Workgroup Member | None | |
| Armstrong, Wendy | Workgroup Member | None | |
| Barsoumian, Alice | Workgroup Member | None | |
| Beeler, Cole | Workgroup Member | None | |
| Bennani, Kenza | Staff | None | |
| Blair, Barbra | Workgroup Member | None | |
| Brennan - Krohn, Thea | Workgroup Member | None | |
| Bryson - Cahn, Chloe | Workgroup Member | None | |
| Cherabuddi, Kartik | Workgroup Member | None | |
| Fong, Gary | Workgroup Member | Critical Innovations, LLC | Advisory/Consultant Role |
| Gaston, David | Workgroup Member | None | |
| Hamilton, Keith | Workgroup Member | None | |
| Holubar, Marisa | Workgroup Member | None | |
| Huang, Misha | Workgroup Member | None | |
| Ince, Dilek | Workgroup Member | Gilead Science’s Clinical Studies for remdesivir | Principal Investigator |
| Accelerate Diagnostics | Research Grants/Contracts | ||
| Leidos | Research Grants/Contracts | ||
| Justo, Julie Ann | Workgroup Member | bioMerieux | Other remuneration - Speaker's Bureau |
| Merck | Advisory/Consultant Role | ||
| Vaxart | Stocks/Bonds | ||
| Kang, Amy | Workgroup Member | None | |
| Larnard, Jeff | Workgroup Member | None | |
| Lee, Matthew | Workgroup Member | None | |
| Logan, Ashleigh | Staff | None | |
| Luther, Vera | Workgroup Member | None | |
| MacDougal, Conan | Workgroup Member | None | |
| Melia, Michael | Workgroup Member | Merck | Organizational Benefit |
| Allergan | Organizational Benefit | ||
| Pfizer; Melinta | Organizational Benefit | ||
| Miller, Matt | Workgroup Member | Abbvie | Honoraria |
| La Jolla | Honoraria | ||
| Merck | Research Grant/Contract | ||
| Moenster, Ryan | Workgroup Member | Shionogi | Advisory/Consultant Role, Honoraria |
| Abbvie/Allergan | Advisory/Consultant Role, Honoraria | ||
| Melinta Therapeutics | Advisory/Consultant Role, Honoraria | ||
| Merck | Advisory/Consultant Role, Honoraria | ||
| Nori, Priya | Workgroup Member | Merck | Co-infections in COVID-19 patients |
| Paras, Molly | Workgroup Member | None | |
| Patel, Payal | Workgroup Member | None | |
| Rodvold, Keith | Workgroup Member | BLC USA LP | Advisory/Consultant Role, Honoraria |
| VenatoRx | Advisory/Consultant Role, Honoraria | ||
| Medicine Company/Qpex Biopharma | Advisory/Consultant Role, Honoraria | ||
| Vemco Med Ed. (Merck CME/CPE programs) | Advisory/Consultant Role, Honoraria | ||
| Debipharm | Advisory/Consultant Role, Honoraria | ||
| Shionogi | Advisory/Consultant Role, Honoraria | ||
| Unrestricted education grant for CME/CPE Program | |||
| Utility Therapeutics | Advisory/Consultant Role, Honoraria | ||
| Janssen | Data Safety Monitoring Board (DSMB) | ||
| Clinartis LLC (projects associated with Spero Therapeutics and Sinovent) | Advisory/Consultant Role, Honoraria | ||
| USCAST : US Ctte on Antimicrobial Susceptibility Testing | Voting Committee Member | ||
| Schooneveld, Trevor | Workgroup Member | Rebiotix, Merk | Research Grant |
| Thermo - Fischer | Speaking | ||
| Schwartz, Brian | Workgroup Member | None | |
| Spicer, Jennifer | Workgroup Member | None | |
| Stack, Conor | Workgroup Member | None | |
| Stead, Wendy | Workgroup Member | None | |
| Stohs, Erica | Workgroup Member | Reviral Ltd | Research Grant |
| Wiley, Zanthia | Workgroup Member | None | |
| Willis, Zachary | Workgroup Member | None | |
| Shnekendorf, Rachel | Staff | None | |
Vaezi, Liza | Workgroup Member | None | |
| Rachel Simmons | Reviewer | None |
Accreditation Statement
In support of improving patient care, IDSA is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME Credit Designation Statement
IDSA designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician participation information will be shared with ABIM through ACCME PARS.
CPE Accreditation Statement for Pharmacists
IDSA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Universal Activity Number (JA0007082-0000-21-004-H01-P) has been assigned to this knowledge-based activity. This activity is acceptable for a maximum of 15 on-demand CPE contact hours (1.5 CEUs) in states that recognize ACPE providers.
Upon completion of this ACPE-approved activity, participants will receive 15 credits that will be automatically uploaded to their NABP e-Profile section of the CPE Monitor. It is the participant's responsibility to upload the correct NABP number to their profile.
Available Credit
- 15.50 ABIM MOC II
- 15.50 ACPE Pharmacy
- 15.50 AMA PRA Category 1 Credit(s)™